Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 6, 2007

View Archived Issues

Novel antiinfective agents disclosed in recent patent literature

Snapshots from the 2007 Gastrointestinal Cancers Symposium: Part I

CF-101 studied for dry eye syndrome in new phase II study

ND-0601 transdermal levodopa patch completes pilot study

DiaKine Therapeutics and AdPharma to develop pipeline for reversing diabetes

Methylphenidate to commence clinical trial for the treatment of cancer-related fatigue

Johnson & Johnson completes acquisition of Conor Medsystems

Starpharma continues studies of microbicide VivaGel

DelSite licenses technology to AriaVax for HIV vaccine

Progress reported in Riquent phase III study

KI-23057 shows preclinical activity against different types of cancer

Neurochem completes North American phase III study of tramiprosate

Generex begins phase II trial for AE-37 in breast cancer

Shionogi and Lilly to codevelop and comarket duloxetine in Japan

Losartan normalizes muscle architecture, repair and function in mouse models of myopathic disorders

Blockade of the orexin OX1/OX2 receptors with ACT-078573 promotes sleep in rats, dogs and humans

Mitsubishi Pharma to merge with Tanabe Seiyaku

Schering-Plough licenses AN-2690 for onychomycosis

Bioral amphotericin set to begin clinical testing

Pivotal Acapodene trials recommended to continue

KI-26894: a novel inhibitor of TGF-beta receptor inhibits tumor growth and prolongs survival in mice

RTP-801i for wet AMD begins phase I study

Erbitux filed in Japan for metastatic colorectal cancer

Recent patents report novel therapeutic agents for metabolic diseases

Wyeth and Nautilus to develop recombinant Factor IX proteins for hemophilia B

Genta completes response to EMEA for Genasense MAA in advanced melanoma

Virginia Commonwealth University and Nicogen jointly divulge novel antismoking agents